Wetin Na Tirzepatid fɔ Lɔs Wɛt?

Sho

Yu de tray tranga wan fɔ lɛf fɔ it bɔku bɔku it ɛn yu de luk fɔ wan fayn sɔlv? Tirzepatid kin bi di ansa we yu bin de luk fɔ.

Tirzepatid   na wan mɛrɛsin we FDA dɔn gri fɔ, we dɛn kin injɛkt wan tɛm insay di wik, we dɛn mek fɔ ɛp fɔ lɔs yu wet ɛn fɔ kɔntrol yu wet. I de wok bay we i de adrɛs di men tin dɛn we kin mek pɔsin gɛt mɔ wet, lɛk fɔ it, fɔ ful-ɔp, ɛn fɔ ɛmti di bɛlɛ.

Insay dis atikul, wi go tɔk bɔt aw tirzepatide kin ɛp fɔ lɛ yu nɔ gɛt bɔku bɔku bɔdi ɛn wetin yu kin ɛkspɛkt frɔm dis nyu tritmɛnt.

Wetin Na Tirzepatid ɛn Aw I De Wok fɔ Wɛt Lɔs?

Ɔndastand di Mɛkanism we Tirzepatid de du

Tirzepatid na fכs in klas dual rεsεpכta agonist we de tכk bכt כl tu di GLP-1 (glucagon lεk pεptida-1) εn GIP (glukose-dipεndεnt insulinotropic polypeptide) rεsεpכta dεm. Dɛn tu ɔmon ya we kɔmɔt na di bɔdi kin kɔmɔt afta dɛn dɔn it, usay dɛn kin ɛp fɔ mek di blɔd shuga, angri, ɛn ful-ɔp. bay we i de falamakata dεn nεchכral signal dεm ya, tirzepatide de ridyus di apεtit, i de mek di satiety, εn slo di digεsshכn, we de mek wan fayn insay envayroment fכ stεdi εn sustainable weit lכs.

Dual Akshɔn: Aw Tirzepatid de Mimik di GLP-1 ɛn GIP Ɔmon fɔ Ɛp fɔ Lɔs di Wɛt

Wetin mek tirzepatide spɛshal na di tu we aw i de wok. Fɔ lɔng tɛm naw, pipul dɛn dɔn no se GLP-1 kin mek pɔsin nɔ want fɔ it ɛn i kin mek pɔsin kɔntrol di glukɔs fayn fayn wan. GIP, we dεn bin כnda εstimat, naw dεn sho se i de εnhans insulin sεnsitiviti εn amplify di fulnes ifekt fכ GLP-1. we dεn tu path dεm ya kam togεda, dεn de mek wan sinajεstik ifekt—sכmtεm rεdukshכn fכ apɛtit, impruv mεtabolik bεlε, εn bכku fεt-bכn pכtεnshal pas singl-rεsεptor mεdikeshכn dεm. Dis de ɛksplen wetin mek tirzepatide kin du bɔku tɛm pas di ol tritmɛnt dɛn we gɛt GLP-1 nɔmɔ.

Apɛtit Kɔntrol ɛn Satiet: Di Rol we Tirzepatid de du fɔ stɔp apɛtit

Tirzepatid de ɛp pipul dɛm fɔ fil ful kwik ɛn fɔ de ful fɔ lɔng tɛm. I de wok pan di sɛnta dɛn we de mek pɔsin want fɔ it na di bren, i de mek di sayn dɛn we de sho se pɔsin want angri ɛn i de mek i nɔ want fɔ it ɔl di de. Dis kin mek am izi fɔ wan wan pipul dɛn fɔ ridyus di kalori we dɛn de it bay insɛf ɛn nɔ fil se dɛn nɔ gɛt bɛtɛ tin fɔ it. As tɛm de go, dis we aw yu de ridyus di kalori dɛn we yu de it ɛvride ɔltɛm, dat kin mek yu lɔs yu bɔdi we gɛt minin.

Slowing Gastric Emptying: Aw dilay we yu de ɛmti yu bɛlɛ kin ɛp fɔ mek yu nɔ gɛt bɔku bɔku bɔdi

bay we i de slo di rεt we di it de kכmכt na di bεlε, tirzepatide de εksεnd di filin fכ ful afta yu it. Dis delay gastric emptying de ɛp fɔ ridyus snek, stabiliz di blɔd shuga spayk afta it, ɛn sɔpɔt portion kɔntrol. di rizulεt na di dijestiv prכsεs we smol, mכr kכntro we de alayns wit hεlth it abit εn lכng tεm we yu de ridyus di wet.

Di Sayns Bihayn Tirzepatid in Effectiveness

Dual Risεptor Aktibכshכn: GIP εn GLP-1 Risεptor dεm in Rol dεm fכ Glukoz Kכntrכl εn Fεt Lכs

di abiliti fכ tirzepatid fכ aktibכt כl tu di GLP-1 εn GIP rεsεpכta dεm de gi mכltipכl mεtabolik advantej dεm. GLP-1 de ɛp fɔ mek di blɔd shuga rigul, i de mek di digest slo, ɛn i de mek i nɔ want fɔ it. GIP de mek di insulin sεnsitiviti bכku εn i de sכpכt di fεt mεtabolism. tכgeda, dεn path dεm ya de mek wan pawaful mεtabolik shift we de mek fεt lכs pas fכ lכs mכsul dεm—we de mek tirzepatide na advans opshכn fכ ridyus di wet we dεn de supavayz.

Inkrεs Insulin Sεnsitiviti: Aw I De Sכpכt Bεtε Blכd Shuga Rεgulεshכn

Bɔrku pipul dɛm wae gɛt fat kin strɛs wit insulin resistance. Tirzepatid de mek di insulin sεnsitiviti bεtεh dεn wan dεm, we de alaw di bכdi fכ yuz glukכs mכr efyushכn. dis nכ de כnli lכs di bכdi shuga lεvεl bכt i de dכn di fεt stכrej εn rεdכks di mεtabolik strεn we de asai fכ fat. Fɔ pipul dɛm we gɛt ɔl tu di fat ɛn tayp 2 dayabitis, tirzepatide de gi tu bɛnifit: klinikli signifyant weit lɔs ɛn impɔtant mɛtabolik wɛlbɔdi.

Udat Go Bɛnifit frɔm Tirzepatid fɔ Wɛt Lɔs?

Dɛn dɔn gri fɔ yuz am fɔ fat ɛn tin dɛn we gɛt fɔ du wit yu wet

Tirzepatid na FDA-apruv fɔ lɔs dɛn wet pan big pipul dɛn we gɛt BMI we na 30 ɔ pas dat, ɔ di wan dɛn we gɛt BMI we pas 27 ɔ pas dat we gɛt wɛlbɔdi prɔblɛm dɛn we gɛt fɔ du wit dɛn wet lɛk aypatɛnshɔn, dayabitis, ɔ obstructive sleep apnea (OSA). Di tebul we de dɔŋ ya de sho aw dɛn dɔn gri fɔ yuz am:

Kɔndishɔn	BMI Rikwaymɛnt	Ɔda Kɔndishɔn dɛn
Fat	BMI ≥ 30. Na 30	Nɔ ɔda kɔndishɔn dɛn nɔ nid fɔ de
Ovaweit wit Wɛlbɔdi Kɔndishɔn	BMI ≥ 27. Na 27	Kɔndishɔn lɛk aypatɛnshɔn, dayabitis
Siviɔs OSA pan Big Pipul dɛn we Fat	BMI ≥ 30. Na 30

Atikul Dɛm Bɛnifit Dɛm: Di Impekt pan Kɔndishɔn Lɛk Obstructive Sleep Apnea (OSA) .

Tirzepatid nɔr de ɛp fɔ lɛf fɔ gɛt bɔku bɔku bɔdi bɔt i de ɛp bak fɔ mek yu gɛt wɛl bɔdi prɔblɛm lɛk OSA, we kin mek yu bɔdi fat pasmak. We dɛn ridyus dɛn wet, di sikman dɛn kin gɛt bɛtɛ slip kwaliti ɛn ɔl dɛn wɛlbɔdi.

Udat Fɔ Avɔyd Tirzepatid?

Tirzepatid nɔ fayn fɔ pipul dɛn we gɛt tayp 1 dayabitis ɔ we gɛt histri bɔt pankrias. I nɔ fayn bak fɔ pipul dɛn we gɛt pasɔnal ɔ famili histri fɔ mɛdula tayroyd kansa (MTC) ɔ Multiple Endocrine Neoplasia type 2 (MEN 2).

Di Krayteria we dɛn fɔ nɔ fɔ tek pat pan di wok	Rizin
Tayp 1 Dayabitis	Dɛn nɔ gri fɔ yuz am pan tayp 1 dayabitis
Istri bɔt Pankriaytis	Risk fɔ gɛt pankrias kin bɔku
MTC ɔ MEN 2	Di risk fɔ gɛt tayroyd tɔŋ dɛn we de go ɔp

Us Rizult Yu Go Ekspekt frɔm Tirzepatid fɔ Wɛt Lɔs?

Avrej Weyt Lɔs Rizult

Tirzepatid dɔn sho impɔtant rizɔlt dɛn pan klinik trial dɛn. Di SURMOUNT-1 trayal sho se di pasɛnt dɛn we yuz tirzepatide (15 mg) fɔ 72 wiks lɔs wan avɛj 22.5% pan dɛn fɔs bɔdi wet. Dis dɔŋ ya na di rizɔlt dɛn we dɛn bays pan difrɛn doz dɛn:

Zepbound Doz we dɛn kin yuz	% Weyt Lɔs na 72 Wik	Avg. We yu de lɔs yu wet (lbs) .	Avg. We yu de lɔs yu wet (kg) .
5 mg/wik fɔ yu	16% .	35,5 lbs we yu de yuz	16,1 kg
10 mg/wik fɔ yu	21.4% .	48,9 lbs	22 kg
15 mg/wik fɔ yu	22,5% na di .	52 lbs we yu de yuz	23,6 kg
Plɛsɛbo we dɛn kɔl	2.4% .	5.3 lbs	2,4 kg

Lɔng Tɛm Rizɔlt: Sɔstayn Wɛt Lɔs insay di Sɔt-Tɛm ɛn Chalenj dɛn fɔ Lɔng Tɛm Weyt Mentɛnans

Pan ɔl we tirzepatide kin mek pɔsin lɔs bɔku bɔku wet insay di fɔs mɔnt dɛn, di klinik trial dɛn dɔn sho se if pɔsin stɔp di mɛrɛsin, i kin mek i gɛt mɔ wet bak. Dis sho se i nid fɔ kɔntinyu fɔ yuz am fɔ mek yu kɔntinyu fɔ gɛt di rizɔlt fɔ lɔng tɛm.

Fɔ Kɔmpia Tirzepatid wit Ɔda Drug dɛn fɔ Lɔs Wɛt

Tirzepatid vs. Semaglutid: Hεd-to-Hεd Kכmpεreshכn כf Tirzepatid in Supiriכr Wεyt Lכs Rizult

Insay di SURMOUNT-5 trayal, dɛn bin si se tirzepatide 47% mɔ ifɛktiv pas semaglutide fɔ lɔs wet. Tirzepatid bin lid to wan avrej weit lכs fכ 50.3 lbs, kכmpεr to 33.1 lbs wit semaglutide. Apat frɔm dat, tirzepatide bin rili ridyus di wes saiz ɛn i bin gɛt ay avɛrej pasɛnt pan di wet we i lɔs.

Aw Yu Go Yuz Tirzepatid fɔ Lɔs Wɛt?

Di we aw dɛn de administret di wok

Dɛn kin gi tirzepatid tru wan injɛkshɔn we dɛn kin put ɔnda di bɔdi wan tɛm insay di wik. Yu kin injekt am ɛni tɛm pan di de, wit it ɔ atɔl it. Di say dɛn we dɛn kin put di injɛkshɔn na di shɔl, di bɛlɛ, ɔ di ɔp an. I fayn fɔ mek yu rɔta di say we dɛn injɛkshɔn wit ɛni doz fɔ mek yu nɔ irita.

Injɛkshɔn Ɛria	Di Bɛst Prɛktis
Fut	Rotate fɔ avɔyd injɛkshɔn sayt iritashɔn
Di bɛlɛ we de na di bɛlɛ	Rotate ɔltɛm fɔ mek yu nɔ irita
Ɔpa Am	I fayn fɔ mek yu ebul fɔ administret yusɛf

Dosing Schedule: Rikɔmɛnd Start Dos ɛn Smɔl smɔl Inkris Bays pan Tolɛreshɔn

di tכpik dכz schedule de stat wit 2.5 mg pan wik, sכmtεm i de inkrεs to 5 mg, 10 mg, כ 15 mg bays pan individyual tכlerεns. Dɛn kin inkrisayz di doz ɛvri 4 wik fɔ mek dɛn nɔ gɛt bɔku sayd ɛfɛkt lɛk nɔs.

Pɔtɛnɛshɛl Chalenj dɛn wit Dosing ɛn Injɛkshɔn

Sayd Ɛfɛkt Manejmɛnt: Tɔk bɔt Kɔmɔn Sayd Ɛfɛkt Lɛk Nɔs ɛn Vɔmit, ɛn Aw fɔ Manej Dɛn

Di kɔmɔn sayd ɛfɛkt dɛm na fɔ nɔs, vɔmit, ɛn dayarɛa. Dɛn tin ya kin apin mɔr insay di fɔs wik dɛm wae dɛn kin gɛt tritmɛnt bɔt bɔrku tɛm kin bɛtɛ as di bɔdi de ajɔst. Fɔ ridyus dɛn tin ya, dɛn kin ɛnkɔrej di wan dɛn we sik fɔ it smɔl smɔl tin dɛn we dɛn kin it ɔltɛm ɛn fɔ gɛt wata.

Injɛkshɔn Sayt Rotashɔn: Bɛst Prɔsis fɔ Rota Injɛkshɔn Sayt fɔ Avɔyd Iriteshɔn

Fɔ mek yu nɔ irita, i impɔtant fɔ de rɔta di say dɛn we dɛn de injɛkshɔn ɔltɛm. Dis kin ɛp fɔ ridyus di risk fɔ mek yu fil pen na di say we yu de, swel, ɔ rɛd we yu de inj yu bɔku tɛm na di sem say.

Wetin Na di Pɔtɛnɛshɛl Sayd Ɛfɛkt dɛm fɔ Tirzepatid?

Di Kɔmɔn Sayd Ɛfɛkt dɛn

Bɔku pipul dɛn kin gɛt smɔl smɔl sik dɛn na dɛn bɛlɛ we dɛn bigin fɔ yuz tirzepatide. Dɛn tin ya kin bi fɔ nɔs, dayarɛa, kɔnstipɛshɔn, blo, ɔ vɔmit as di dijestiv sistɛm de adap fɔ ɛmti di bɛlɛ sloslo. Dɛn tin ya kin apin fɔ sɔm tɛm ɛn bɔku tɛm kin bɛtɛ insay sɔm wiks we dɛn kɔntinyu fɔ yuz am. If yu it smɔl smɔl tin dɛn, yu nɔ gɛt bɔku wata, ɛn nɔ it tin dɛn we gɛt bɔku fat we yu de trit yu kwik, dat kin ɛp fɔ mek yu nɔ fil fayn.

Riakshɔn dɛn na di sayt we dɛn put di injɛkshɔn: Lokal Pen ɔ Swɛlin frɔm di Injɛkshɔn

Sɔm pipul dɛn we de yuz am kin notis se i de rɛd, i de it, ɔ i de swel smɔl na di say we dɛn injekt am. Dɛn riakshɔn ya nɔ kin bad ɛn dɛn kin dɔn kwik kwik wan. We yu de rɔta di say dɛn we dɛn de injɛkshɔn—di shɔl, bɛlɛ, ɔ ɔp an—de ɛp fɔ mek yu nɔ irita. If yu yuz di rayt we fɔ injɛkshɔn ɛn alaw di mɛrɛsin fɔ rich na rum tɛmpracha bifo yu yuz am, dat kin mek yu nɔ fil fayn bak.

Siriɔs Sayd Ɛfɛkt ɛn Prɛkɔshɔn

Galblada Isyu ɛn Pankriaytis: Risk fɔ mek yu gɛt siriɔs bɛlɛ pen ɛn wetin fɔ wach fɔ

Sɔntɛm, tirzepatide kin mek yu gɛt prɔblɛm wit di gal blad ɔ pankrias. Di sayn dɛm we de sho se yu de wɔn yu na yu bɛlɛ we yu de fil wantɛm wantɛm, we yu de fil bad bad wan, we yu de fil pen na yu bak, we yu de vɔmit ɔltɛm, fiva, ɔ janda (we yu skin ɔ yu yay de yɔlɔ). Bikɔs pankrias kin mek pɔsin in layf de pan denja, ɛni bad bad ɔ we de kɔntinyu fɔ fil pen na in bɛlɛ, pɔsin we de kia fɔ wɛlbɔdi biznɛs fɔ chɛk am wantɛm wantɛm.

Tayroyd ɛn Mental Ɛlth Wɔnin: Di Nid fɔ Monitorin Bikɔs ɔf di Pɔtɛnɛshɛl fɔ Tayrɔyd Isyu ɔ Chenj na di Mud

Tirzepatid kin kɛr wan bɔks wɔnin bɔt di risk we kin mek pɔsin gɛt tayroyd C-sɛl tɔmɔs. Pan ɔl we i nɔ kin apin so ɔltɛm, di wan dɛn we de yuz am fɔ wach fɔ si if i gɛt sɔm sayn dɛn lɛk we gɛt smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl smɔl. Ɛni wan pan dɛn sayn ya fɔ mek dɛn chɛk am kwik kwik wan. Di chenj we dɛn kin chenj di we aw dɛn de fil kin apin bak pan pipul dɛn we gɛt sɛns. Fɔ fil bɔt pwɛl hat, wɔri, ɔr nɔrmal bihayvya chenj fɔ ripɔt to wɛl bɔdi prɔvayda witout delay.

Yu kin Mek Yu Wet Afta Yu Stɔp Tirzepatid?

We Yu Gɛt bak afta yu dɔn stɔp fɔ yuz am

Bɔku pipul dɛn kin wɔnda if di wet we pɔsin kin lɔs frɔm tirzepatide kin las afta dɛn dɔn stɔp di tritmɛnt. Klinik stɔdi dɛn sho se fɔ gɛt mɔ wet bak na kɔmɔn tin wans dɛn dɔn stɔp fɔ tek di mɛrɛsin. Insay di SURMOUNT-4 trayal, di patisipan dɛm we bin stɔp tirzepatide bin gɛt bak lɛk 14% pan di wet we dɛn bin dɔn lɔs, ivin wit rɛgyula fɔlɔp. Dis kin apin bikɔs di apɛtit-suprɛs ɛn mɛtabolik ifɛkt dɛm we tirzepatide gɛt nɔ de sɔpɔt igen fɔ ridyus kalori intake wans di tritmɛnt dɔn stɔp. Dɛn tin ya we dɛn fɛn sho se tirzepatide de wok fayn fayn wan as pat pan wan strateji fɔ kia fɔ lɔng tɛm pas fɔ fiks fɔ shɔt tɛm.

Kronik Manejmɛnt fɔ Ɔbisiti: Tirzepatid as Lɔng Tɛm Sɔlwɛshɔn fɔ Wɛt Manejmɛnt

Naw dɛn dɔn no se fɔ fat na sik we nɔ de dɔn, we kin kam bak—lɛk ay blɔd prɛshɔn ɔ dayabitis. Dat min se fɔ kɔntinyu fɔ du di manejmɛnt impɔtant. Tirzepatid de gi mεtabolik sכpכt we de εp pipul dεm fכ mεnten lכw angri lεvεl, bεtεh fכ kכntrכl glukכs, εn fכ it hεlth. We yu yuz am ɔltɛm, i kin mek di wet we yu de yuz fɔ lɔng tɛm, nɔ de chenj ɛn i kin mek yu nɔ ebul fɔ saikl yu wet. Fɔ bɔku pipul dɛn, tirzepatide kin bi pat pan wan kɔmprɛhnsiv, lɔng tɛm obesity tritmɛnt plan pas fɔ bi wan tɛmporari mɛrɛsin.

Aw fɔ Avɔyd fɔ Gɛt Wɛt bak

Tin dɛn fɔ tink bɔt aw fɔ yuz am fɔ lɔng tɛm: Di Impɔtant fɔ Mek di Tritmɛnt kɔntinyu fɔ gɛt sakrifays

Fɔ mek dɛn kɔntinyu fɔ lɔs dɛn wet, bɔku tɛm di sik pipul dɛn kin nid fɔ kɔntinyu fɔ yuz tirzepatide pas di fɔs tritmɛnt pat. di tεrapi we de kכntinyu de εp fכ kip di impruvmεnt dεm na di apεtit kכntrכl εn mεtabolik fכnshכn. Di wan dɛn we de kia fɔ wɛlbɔdi biznɛs kin ajɔst di doz ɔ rɛkɔmɛnd mentenɛns-lɛvɛl tritmɛnt dipen pan di wan wan prɔgrɛs ɛn di sayd ɛfɛkt tolɛreshɔn. We yu de chɛk-in ɔltɛm, dat kin ɛp bak fɔ mek shɔ se di tritmɛnt kɔntinyu fɔ wok ɛn sef as tɛm de go.

Supplementing wit Laif Stayl Chenj: Di Rol we di it ɛn ɛksesaiz de du fɔ mek yu gɛt wet afta yu dɔn stɔp fɔ tek mɛrɛsin

Mɛrɛsin nɔmɔ nɔ go ebul fɔ gi garanti fɔ se i go gɛt am fɔ ɔltɛm. Fɔ mek yu gɛt bɔku bɔku wet, yu nid fɔ de liv yu layf ɔltɛm. Wan balans it wit di pat dɛn we pɔsin kin ebul fɔ manej, fɔ du bɔku bɔku tin dɛn ɔltɛm, ɛn fɔ klin fɔ slip fayn, ɔl de ple impɔtant pat fɔ sɔpɔt fɔ mek pɔsin gɛt bɔku bɔku wet fɔ lɔng tɛm. Dɛn abit ya kin ɛp fɔ mek di prɔgrɛs we dɛn dɔn gɛt wit tirzepatide strɔng ɛn mek di chenj izi if dɛn ridyus di mɛrɛsin ɔ lɛf di mɛrɛsin leta. Di wan dɛn we de kɔba tirzepatide wit wɛlbɔdi rutin kin gɛt mɔ we fɔ kip dɛn wet ɛn avɔyd di kwik we aw dɛn kin gɛt bak kwik kwik wan we dɛn kin si na klinik stɔdi.

Dɔn

Tirzepatid de gi strɔng sɔpɔt fɔ pipul dɛm wae de gɛt fɔ fat ɔr wae gɛt fɔ du wit dɛn wet. I de mek pɔsin nɔ want fɔ it, i de mek pɔsin ful-ɔp, ɛn i de ɛp fɔ mek di blɔd shuga rigul fɔ mek i ebul fɔ kɔntrol di wet fayn fayn wan. Yu kin nid fɔ yuz am fɔ lɔng tɛm ɛn fɔ gɛt wɛlbɔdi abit fɔ mek yu kɔntinyu fɔ gɛt di rizɔlt. Cocer PeptidesTM de gi ay kwaliti tirzepatide sɔlvishɔn dɛn we dɛn mek fɔ sɔpɔt bɛtɛ autkam ɛn lɔng tɛm wet mɛnejɛmɛnt sakrifays.

FAQ we dɛn kin aks

K: Wetin na tirzepatide fɔ lɔs yu wet?

A: Tirzepatid na injɛkshɔn we dɛn kin gi ɛvri wik we kin ɛp fɔ ridyus di apɛtit ɛn sɔpɔt fɔ lɛf fɔ it bɔku bɔku it.

K: Aw tirzepatide de ɛp fɔ mek yu nɔ gɛt bɔku bɔku bɔdi?

A: Tirzepatid de wok bay we i de mek yu ful-ɔp mɔ ɛn mɔ ɛn slo di dijeshɔn, we de sɔpɔt fɔ lɔs yu wet ɔltɛm.

K: Udat fɔ tink bɔt tirzepatide fɔ mek yu nɔ gɛt bɔku bɔku bɔdi?

A: Tirzepatid kin ɛp big pipul dɛn we fat ɔ we gɛt fɔ du wit dɛn wet fɔ mek dɛn lɔs dɛn wet we gɛt minin.

K: Yu tink se tirzepatide de wok pas ɔda mɛrɛsin dɛn we de mek pɔsin nɔ gɛt bɔku bɔku bɔdi?

A: Bɔku tɛm, Tirzepatid kin mek pɔsin lɔs mɔ wet we yu kɔmpia am wit di sem kayn mɛrɛsin dɛn.

K: Wetin a fɔ du if tirzepatide mek a gɛt sayd ɛfɛkt?

A: Mild sayd ɛfɛkt kin apin; tɔk wit yu prɔvayda if di sayn dɛn stil de we dɛn de trit di tirzepatide.